• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胱氨酸尿症:发病机制与治疗管理。

Cystinuria: mechanisms and management.

机构信息

Division of Pediatric Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, USA.

出版信息

Pediatr Nephrol. 2012 Nov;27(11):2031-2038. doi: 10.1007/s00467-011-2092-6. Epub 2012 Jan 27.

DOI:10.1007/s00467-011-2092-6
PMID:22281707
Abstract

Cystinuria is a relatively uncommon cause of pediatric stone disease, but has significant morbidity if not properly controlled because of its significant stone recurrence rate. Cystinuria is caused by the inability of the renal tubules to reabsorb filtered cystine, which is poorly soluble at a typical urine pH <7. Although many advances have been made in the understanding of the genetic and physiological basis of cystinuria, the cornerstones of treatment still involve stone prevention with dietary measures and pharmacological therapy, coupled with surgical interventions for stone removal. Pharmacological treatments can carry significant side effects that must be monitored and can limit therapy as well as impede compliance. Most patients will require surgical intervention for stone removal, although compliance with prevention strategies reduces the need for intervention.

摘要

胱氨酸尿症是儿童结石病的一个相对少见的病因,但如果得不到适当控制,其结石复发率很高,会导致严重的发病率。胱氨酸尿症是由于肾脏小管无法重吸收滤过的胱氨酸所致,在典型的尿 pH 值<7 时,胱氨酸的溶解度较低。尽管在理解胱氨酸尿症的遗传和生理基础方面已经取得了许多进展,但治疗的基石仍然包括通过饮食措施和药物治疗进行结石预防,以及进行手术干预以去除结石。药物治疗可能会带来严重的副作用,必须进行监测,这可能会限制治疗并影响患者的依从性。大多数患者需要进行手术干预以去除结石,尽管遵守预防策略可以减少干预的需求。

相似文献

1
Cystinuria: mechanisms and management.胱氨酸尿症:发病机制与治疗管理。
Pediatr Nephrol. 2012 Nov;27(11):2031-2038. doi: 10.1007/s00467-011-2092-6. Epub 2012 Jan 27.
2
A comparison of the effects of potassium citrate and sodium bicarbonate in the alkalinization of urine in homozygous cystinuria.枸橼酸钾和碳酸氢钠对纯合子胱氨酸尿症患者尿液碱化作用的比较。
Urol Res. 2001 Oct;29(5):295-302. doi: 10.1007/s002400100200.
3
[Cystinuria in children: A report of 4 cases].[儿童胱氨酸尿症:4例报告]
Arch Pediatr. 2011 May;18(5):553-7. doi: 10.1016/j.arcped.2011.02.022. Epub 2011 Apr 2.
4
Cystinuria.胱氨酸尿症
Semin Nephrol. 2008 Mar;28(2):181-91. doi: 10.1016/j.semnephrol.2008.01.011.
5
How should patients with cystine stone disease be evaluated and treated in the twenty-first century?在21世纪,胱氨酸结石病患者应如何进行评估和治疗?
Urolithiasis. 2016 Feb;44(1):65-76. doi: 10.1007/s00240-015-0841-x. Epub 2015 Nov 27.
6
Cystinuria: current diagnosis and management.胱氨酸尿症:当前的诊断与管理。
Urology. 2014 Apr;83(4):693-9. doi: 10.1016/j.urology.2013.10.013. Epub 2013 Nov 16.
7
[Cystinic nephrolythiasis: clinical experience and new diagnostic and therapeutic perspectives].[胱氨酸肾结石病:临床经验及新的诊断与治疗前景]
G Ital Nefrol. 2016 May-Jun;33(3).
8
Cystinuria: current concepts and future directions.胱氨酸尿症:当前概念与未来方向
Clin Nephrol. 2015 Mar;83(3):138-46. doi: 10.5414/cn108514.
9
[Clinical study on cystinuria in children--the stone management and the prevention of calculi recurrence].儿童胱氨酸尿症的临床研究——结石处理与预防结石复发
Nihon Hinyokika Gakkai Zasshi. 1998 Sep;89(9):758-65. doi: 10.5980/jpnjurol1989.89.758.
10
[Modulation of the phenotypic expression in the patient with cystinuria: influence of therapeutic intervention and diet].[胱氨酸尿症患者表型表达的调节:治疗干预和饮食的影响]
Arch Esp Urol. 2007 Mar;60(2):109-18. doi: 10.4321/s0004-06142007000200002.

引用本文的文献

1
Cystinuria in children: diagnosis and treatment.儿童胱氨酸尿症:诊断与治疗
World J Urol. 2025 Apr 15;43(1):226. doi: 10.1007/s00345-025-05604-6.
2
Exosomal proteomics in kidney disease: From technical approaches to clinical applications.肾脏疾病中的外泌体蛋白质组学:从技术方法到临床应用
J Food Drug Anal. 2022 Jun 15;30(2):202-222. doi: 10.38212/2224-6614.3409.
3
Risk factors for recurrence in pediatric urinary stone disease.小儿尿路结石病复发的危险因素。

本文引用的文献

1
Chronic kidney disease in kidney stone formers.肾结石患者的慢性肾脏病。
Clin J Am Soc Nephrol. 2011 Aug;6(8):2069-75. doi: 10.2215/CJN.10651110. Epub 2011 Jul 22.
2
Crystal growth inhibitors for the prevention of L-cystine kidney stones through molecular design.通过分子设计抑制 L-胱氨酸肾结石的晶体生长。
Science. 2010 Oct 15;330(6002):337-341. doi: 10.1126/science.1191968.
3
Three pathways for human kidney stone formation.人类肾结石形成的三种途径。
Pediatr Nephrol. 2024 Jul;39(7):2105-2113. doi: 10.1007/s00467-024-06300-0. Epub 2024 Jan 25.
4
Typical course of cystinuria leading to untypical complications in pregnancy: A case report and review of literature.胱氨酸尿症导致妊娠非典型并发症的典型病程:一例病例报告及文献综述
Front Med (Lausanne). 2023 Apr 6;10:1097442. doi: 10.3389/fmed.2023.1097442. eCollection 2023.
5
Urinary stone disease in Syrian children.叙利亚儿童的尿路结石病。
Pediatr Nephrol. 2023 Aug;38(8):2699-2709. doi: 10.1007/s00467-022-05860-3. Epub 2023 Jan 20.
6
Phenotypic characterization of a pediatric cohort with cystinuria and usefulness of newborn screening.胱氨酸尿症儿科队列的表型特征及新生儿筛查的效用
Pediatr Nephrol. 2023 May;38(5):1513-1521. doi: 10.1007/s00467-022-05732-w. Epub 2022 Oct 13.
7
Cystine crystal-induced reactive oxygen species associated with NLRP3 inflammasome activation: implications for the pathogenesis of cystine calculi.胱氨酸晶体诱导的活性氧与 NLRP3 炎性体激活相关:对胱氨酸结石发病机制的影响。
Int Urol Nephrol. 2022 Dec;54(12):3097-3106. doi: 10.1007/s11255-022-03347-6. Epub 2022 Sep 10.
8
Comparative and Selective Interaction of Amino Acid d-Cysteine with Colloidal Gold Nanoparticles in the Presence of a Fluorescent Probe in Aqueous Medium.在水介质中荧光探针存在的情况下,氨基酸d-半胱氨酸与胶体金纳米颗粒的比较性和选择性相互作用。
ACS Omega. 2022 Aug 12;7(33):29013-29026. doi: 10.1021/acsomega.2c02725. eCollection 2022 Aug 23.
9
Cystinuria: An Overview of Diagnosis and Medical Management.胱氨酸尿症:诊断与药物治疗概述
Turk Arch Pediatr. 2022 Jul;57(4):377-384. doi: 10.5152/TurkArchPediatr.2022.22105.
10
Cystinuria: An Overview of Challenges and Surgical Management.胱氨酸尿症:挑战与外科治疗概述
Front Surg. 2022 Jun 16;9:812226. doi: 10.3389/fsurg.2022.812226. eCollection 2022.
Urol Res. 2010 Jun;38(3):147-60. doi: 10.1007/s00240-010-0271-8. Epub 2010 Apr 22.
4
New horizons in the management of patients with cystinuria.胱氨酸尿症患者管理的新领域。
Curr Opin Urol. 2010 Mar;20(2):169-73. doi: 10.1097/MOU.0b013e328333b674.
5
Extracorporeal shock wave lithotripsy in prepubertal children: 22-year experience at a single institution with a single lithotriptor.青春期前儿童的体外冲击波碎石术:一家机构使用单一碎石机的22年经验。
J Urol. 2009 Oct;182(4 Suppl):1835-9. doi: 10.1016/j.juro.2009.04.084. Epub 2009 Aug 18.
6
Kidney stones and the risk for chronic kidney disease.肾结石与慢性肾脏病风险
Clin J Am Soc Nephrol. 2009 Apr;4(4):804-11. doi: 10.2215/CJN.05811108. Epub 2009 Apr 1.
7
Penicillamine therapy for pediatric cystinuria: experience from a cohort of American children.青霉胺治疗小儿胱氨酸尿症:一组美国儿童的经验
J Urol. 2008 Dec;180(6):2620-3. doi: 10.1016/j.juro.2008.08.057. Epub 2008 Oct 31.
8
Identification of novel cystinuria mutations in pediatric patients.小儿胱氨酸尿症新突变的鉴定。
J Pediatr Urol. 2006 Dec;2(6):575-8. doi: 10.1016/j.jpurol.2005.11.011. Epub 2006 Jan 19.
9
Multi-system disorder syndromes associated with cystinuria type I.与I型胱氨酸尿症相关的多系统障碍综合征。
Curr Mol Med. 2008 Sep;8(6):544-50. doi: 10.2174/156652408785747997.
10
Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate.乙酰唑胺是一种有效的辅助药物,用于对枸橼酸钾治疗无效的尿酸和胱氨酸结石形成患者的尿液碱化。
Urology. 2008 Aug;72(2):278-81. doi: 10.1016/j.urology.2008.04.003. Epub 2008 Jun 4.